In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart.

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more expensive when valued on FCF -- about 103 times. These might be acceptable valuations if earnings were to continue tripling year after year. In fact, though, analysts see profits growing only 13% this year, and perhaps 57% next.

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers using personalized treatment plans.